Intra-Cellular Therapies Inc. (ITCI) financial statements (2021 and earlier)

Company profile

Business Address 430 EAST 29TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments601085546438447561
Cash and cash equivalents601085538494761
Short-term investments   427335428 
Restricted cash and investments1      
Receivables11   000
Inventory, net of allowances, customer advances and progress billings7      
Inventory7      
Prepaid expense  2    
Other undisclosed current assets61212329854870
Total current assets:691230355469388483131
Noncurrent Assets
Operating lease, right-of-use asset2418
Property, plant and equipment2211110
Other noncurrent assets0000000
Deferred tax assets, net11   
Other undisclosed noncurrent assets 0     
Total noncurrent assets:262122110
TOTAL ASSETS:717251357471389484131
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2023168533
Accounts payable67146422
Employee-related liabilities151522111
Debt 3     
Other undisclosed current liabilities1610206538
Total current liabilities:3736361411611
Noncurrent Liabilities
Long-term debt and lease obligation2420     
Operating lease, liability2420
Liabilities, other than long-term debt  3332 
Deferred revenue and credits332 
Deferred rent credit  3
Other undisclosed noncurrent liabilities(24)      
Total noncurrent liabilities:24203332 
Total liabilities:6056391713811
Stockholders' equity
Stockholders' equity attributable to parent, including:657195318454376476121
Common stock0000000
Common stock, value, subscriptions      0
Additional paid in capital1,593905881862685670209
Accumulated other comprehensive income (loss)00(1)(1)(0)(1)(0)
Accumulated deficit(937)(710)(562)(407)(309)(193)(88)
Other undisclosed stockholders' equity attributable to parent      (0)
Total stockholders' equity:657195318454376476121
TOTAL LIABILITIES AND EQUITY:717251357471389484131

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net0001
Gross profit:230 0001
Operating expenses(254)(154)(162)(103)(119)(106)(42)
Other undisclosed operating income      10
Operating loss:(231)(154)(162)(103)(118)(106)(31)
Nonoperating income
(Investment Income, Nonoperating)
4674310
Interest and debt expense    (0) (0)
Loss from continuing operations before income taxes:(227)(148)(155)(99)(115)(105)(31)
Income tax expense (benefit)(0)(0)(0)1(1)(0)(0)
Net loss available to common stockholders, diluted:(227)(148)(155)(98)(116)(105)(31)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(227)(148)(155)(98)(116)(105)(31)
Other comprehensive income (loss)010(0)0(0)(0)
Comprehensive loss, net of tax, attributable to parent:(227)(147)(155)(98)(116)(105)(31)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: